Clinical Trials Browser

Sarcoma, Alveolar Soft Part

Sarcoma, Sarcoma, Alveolar Soft Part

Ovarian Neoplasms

Ovarian Neoplasms

Glioblastoma, Gliosarcoma

Ovarian Neoplasms

Endometrial Adenocarcinoma

Prostatic Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Uveal Melanoma, Melanoma

Prostatic Neoplasms

Ovarian Neoplasms

Carcinoma, Non-Small-Cell Lung

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Congenital Abnormalities, Leukemia, Myeloid, Acute

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

Advanced Breast Cancer

Carcinoma, Renal Cell

Breast Neoplasms, Breast Neoplasms, Male

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Carcinoma, Non-Small-Cell Lung

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Uterine Cervical Neoplasms

Brain Neoplasms, Glioblastoma, Gliosarcoma

Carcinoma, Hepatocellular

Leukemia, Lymphocytic, Chronic, B-Cell

Colorectal Neoplasms

Hypertension, Neoplasms

Neoplasms, Sarcoma, Gastrointestinal Stromal Tumors

Clinical Trials

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

BAROCCO

OCTOVA

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

CONCERTO

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

AZD2171 to Treat Prostate Cancer

Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery

A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)

AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer

AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery

AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer

AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)

HORIZON I

Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours

The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).